HALO

Q: What is the price of Halozyme Therapeutics (HALO) today?

The price of Halozyme Therapeutics (HALO) today is US$ 64,10, with a variation of 22.96% compared to the last year. The price of Halozyme Therapeutics (HALO) started the year trading around US$ 47,81 and today it is at US$ 64,10. Follow the real-time price chart, the historical price of Halozyme Therapeutics (HALO), and stock data from Ibovespa and international markets.

Q: When does Halozyme Therapeutics (HALO) pay dividends?

Halozyme Therapeutics (HALO) did not distribute dividends in the last year.

Q: Halozyme Therapeutics (HALO) is it worth it?

Currently, Halozyme Therapeutics (HALO) is priced at US$ 64,10, with a P/E of 14,26%, representing a deviation of 19,71% from its historical average P/E. In the last year, the stock showed a variation of 22.96% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 22,96%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy stocks of Halozyme Therapeutics (HALO)?

Investing in stocks of Halozyme Therapeutics (HALO) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 stocks of Halozyme Therapeutics (HALO) yield today?

The yield of Halozyme Therapeutics (HALO) was -15,44% in the last month, 22,96% in the last year and 124,87% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 stocks of Halozyme Therapeutics (HALO) today, the total investment would be US$ 6.410,00, based on the current price of US$ 64,10.If past performance were to repeat, the return on your investment would be:In 1 year: US$ 7.881,74In 5 years: US$ 14.414,17In 10 years: 30.754,54It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Halozyme Therapeutics Inc.

Price

US$ 64,10

variation (12m)

22,96%

p/l

14,26

p/vp

25,08

DIVIDEND YIELD

0,00%

price HALO

BVMF

HALO

If you had invested

years ago

6 months

1 year

5 years

10 years

ago, today you would have

ago, today you would have:

*The figure considers the reinvestment of dividends.

Profitability of HALO

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

-15,44%

3 months

12,16%

1 year

22,96%

2 years

75,42%

5 years

124,87%

10 years

379,79%

real profitability

profitability minus inflation.

1 month

-15,44%

3 months

11,75%

1 year

17,57%

2 years

60,11%

5 years

66,17%

10 years

187,26%

Indicators HALO

check out the fundamentals of Halozyme Therapeutics shares

P/E

14,26

Sector: -3,47 Industry: -3,47

P/SALES RATIO (PSR)

6,87

Sector: -4,23 Industry: -4,23

P/BV

25,08

Sector: 1,89 Industry: 1,89

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

28,50%

Sector: -63,87% Industry: -63,87%

ROE

175,93%

Sector: -70,87% Industry: -70,87%

ROIC

48,89%

Sector: -2.084,36% Industry: -2.084,36%

NET MARGIN

48,21%

Sector: -41,75% Industry: -41,75%

GROSS MARGIN

84,91%

Sector: 38,19% Industry: 38,19%

OPERATING MARGIN

59,45%

Sector: -41,04% Industry: -41,04%

P/EBITDA

10,04

Sector: -3,65 Industry: -3,65

P/EBIT

11,13

Sector: -3,64 Industry: -3,64

P/ASSET

4,06

Sector: 1,41 Industry: 1,41

BVPS

2,75

Sector: 1,84 Industry: 1,84

EPS

4,84

Sector: -2,20 Industry: -2,20

EQUITY / ASSETS

0,16

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

31,61%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

27,85%

Sector: - Industry: -

FAIR PRICE OF Halozyme Therapeutics ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 64,10

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

-73,00%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

HALO indicators history

DRAG THE FRAME TO SEE MORE DATA

Stocks comparator

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	net margin
JNJ	17,80	5,78	32,50%	2,69%	US$ 453,87 B	27,75%
PFE	16,92	1,75	10,33%	6,25%	US$ 155,60 B	15,13%
ABBV	108,79	-2.966,40	-2.726,81%	2,79%	US$ 409,36 B	6,45%
NVO	16,20	10,21	62,99%	2,83%	US$ 265,17 B	34,74%
MRK	12,67	4,56	36,03%	3,59%	US$ 223,87 B	28,16%
AZN	28,39	5,90	20,79%	1,83%	US$ 264,46 B	16,23%
BMY	17,97	5,29	29,44%	5,41%	US$ 92,49 B	10,71%
GILD	19,99	7,16	35,82%	2,79%	US$ 140,30 B	24,71%
ZTS	24,61	13,09	53,20%	1,32%	US$ 65,16 B	28,00%
REGN	13,97	2,10	15,06%	0,44%	US$ 63,00 B	31,83%
AMGN	30,70	21,58	70,29%	3,15%	US$ 160,26 B	14,67%
VRTX	28,59	6,03	21,11%	0,00%	US$ 103,65 B	31,22%
MCK	24,89	-106,90	-429,55%	0,40%	US$ 92,26 B	0,97%
CAH	26,56	-13,96	-52,54%	1,31%	US$ 36,76 B	0,60%
ADMA	17,05	8,87	52,03%	0,00%	US$ 3,53 B	43,51%
BIIB	13,23	1,33	10,08%	0,00%	US$ 23,50 B	17,46%
HRMY	8,91	2,01	22,58%	0,00%	US$ 1,55 B	22,19%

comparison of HALO with indexes

If you had invested (change) 2 years years ago, ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

Dividend History HALO

current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY Halozyme Therapeutics

Halozyme Therapeutics Inc.

Average user rating I10

4.0 (47 people)

Estados Unidos

27 years

Foundation: 1998

2004

Year of debut on the stock exchange - 21 years

132

Employees

Additional Information

The Company Halozyme Therapeutics Inc. (Estados Unidos), is listed on Nasdaq with a market value of $ 8,35 Billions, having a net worth of $ 332,75 Milhões.

With a total of 132 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 1,21 Billion, which generated a profit in the amount of $ 585,42 Milhões.

As for its main indicators, the Company has a P/E ratio of 14,26, a P/BV ratio of 25,08 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker HALO.

Market value

US$ 8,35 Billions

Net worth

US$ 332,75 Milhões

US$ 332.750.000,00

Assets

US$ 2,05 Billions

US$ 2.053.900.000,00

Total Number of Shares

121,00 Milhões

121.000.000

Average Daily Trading Volume

US$ 2,13 Milhões

US$ 2.134.812,00

Sector

Health Care

Industry

Biotechnology

HALO

HALO revenue and profits

HALO results

DRAG THE FRAME TO SEE MORE DATA

HALO cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12 M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12 M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12 M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12 M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12 M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12 M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12 M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

Frequently Asked Questions

What is the price of Halozyme Therapeutics (HALO) today?

The price of Halozyme Therapeutics (HALO) today is US$ 64,10, with a variation of 22.96% compared to the last year. The price of Halozyme Therapeutics (HALO) started the year trading around US$ 47,81 and today it is at US$ 64,10. Follow the real-time price chart, the historical price of Halozyme Therapeutics (HALO), and stock data from Ibovespa and international markets.

When does Halozyme Therapeutics (HALO) pay dividends?

Halozyme Therapeutics (HALO) did not distribute dividends in the last year.

Halozyme Therapeutics (HALO) is it worth it?

Currently, Halozyme Therapeutics (HALO) is priced at US$ 64,10, with a P/E of 14,26%, representing a deviation of 19,71% from its historical average P/E. In the last year, the stock showed a variation of 22.96% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 22,96%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy stocks of Halozyme Therapeutics (HALO)?

Investing in stocks of Halozyme Therapeutics (HALO) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 stocks of Halozyme Therapeutics (HALO) yield today?

The yield of Halozyme Therapeutics (HALO) was -15,44% in the last month, 22,96% in the last year and 124,87% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 stocks of Halozyme Therapeutics (HALO) today, the total investment would be US$ 6.410,00, based on the current price of US$ 64,10.

If past performance were to repeat, the return on your investment would be:

In 1 year: US$ 7.881,74
In 5 years: US$ 14.414,17
In 10 years: 30.754,54

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

HALO

Halozyme Therapeutics Inc.

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

Profitability of HALO

check out the fundamentals of Halozyme Therapeutics shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years years ago, ago, today you would have

current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY Halozyme Therapeutics

Halozyme Therapeutics Inc.

Estados Unidos

27 years

2004

132

Additional Information

PROFIT X PRICE HALO

HALO results

HALO cash flow

evolution of assets - HALO

HALO balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

Frequently Asked Questions